Veracyte Moves Into Lung Cancer MolDx With $21 Million Allegro Buy
This article was originally published in The Gray Sheet
Executive Summary
The molecular diagnostic firm is expanding its focus beyond thyroid cancer to lung cancer, with plans to acquire Allegro Diagnostics and its gene expression assay. Allegro’s in-development system offers enhanced risk assessment for the approximately 40 percent of bronchoscopies that are inconclusive for lung cancer.